

***CIBMTR is a collaborative resource of data and experts supporting research in cellular therapies to improve patient outcomes.***

**CIBMTR strategy is organized into 5 pillars:**



## ASH ABSTRACTS: Saturday, December 7, 2024

Title	Status	Time/Session	Presenter
24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702	Oral	9:30 AM - 11:00 AM Presentation: 10:00 AM Session: 653	Rahul Banerjee
Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL) Clinically Relevant Abstract	Oral	9:30 AM - 11:00 AM Presentation: 10:30 AM Session: 628	Alaa Ali
Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207	Poster	5:30 PM - 7:30 PM Session: 721	Akshay Sharma
Single-Agent Ibrutinib Versus Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and del(17p)	Poster	5:30 PM - 7:30 PM Session: 732	Farrukh Awan
Identifying Disparities in Autologous Hematopoietic Cell Transplantation (autoHCT) Utilization for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in California	Poster	5:30 PM - 7:30 PM Session: 906	Naseem Esteghamat
Impact of Extramedullary Disease on the Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Acute Myeloid Leukemia - a CIBMTR Analysis	Poster	5:30 PM - 7:30 PM Session: 908	Hemalatha Rangarajan

## ASH ABSTRACTS: Sunday, December 8, 2024

Title	Status	Time/Session	Presenter
Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry	Oral	9:30 AM - 11:00 AM Presentation: 9:45 AM Session: 626	Maria Bobillo
Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry	Oral	9:30 AM - 11:00 AM Presentation: 10:15 AM Session: 626	Sairah Ahmed
Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)	Oral	9:30 AM - 11:00 AM Presentation: 10:15 AM Session: 906	Dasom (Caroline) Lee
Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report	Oral	9:30 AM - 11:00 AM Presentation: 10:30 AM Session: 906	Jiasheng Wang

**continued on next page ...**

... continued from previous page

Title	Status	Time	Presenter
Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)	Oral	12:00 PM - 1:30 PM Presentation: 12:30 PM Session: 906	Christopher Strouse
The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704	Oral	4:30 PM - 6:00 PM Presentation: 4:30 PM Session: 721	Mohamed Sorror
Immunoepitidome Divergence between Mismatched HLA Haplotypes and Survival after Haploidentical HCT: A Retrospective Study from the CIBMTR	Oral	4:30 PM - 6:00 PM Presentation: 4:45 PM Session: 732	Katharina Fleischhauer
Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702	Oral	4:30 PM - 6:00 PM Presentation: 5:30 PM Session: 732	Stephanie Lee
Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia	Poster	6:00 PM - 8:00 PM Session: 619	Laura Dillon
Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/ Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment	Poster	6:00 PM - 8:00 PM Session: 651	Dimitra Karagkouni
OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation	Poster	6:00 PM - 8:00 PM Session: 721	Jeffery Auletta
Addressing Patient Representation in Hematopoietic Cell Transplant Clinical Trials: Insights Gained through the Access Trial	Poster	6:00 PM - 8:00 PM Session: 903	Jeffery Auletta
Comparing Access to Allogeneic Hematopoietic Cell Transplant across the United States: Physician Density, Minority Health Social Vulnerability Index, Transplant Unmet Need and Utilization	Poster	6:00 PM - 8:00 PM Session: 903	Samantha Watters

## ASH ABSTRACTS: Monday, December 9, 2024

Title	Status	Time	Presenter
Uncovering the Genetics of Poor and Exceptional Survivorship after Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (HCT)	Oral	2:45 PM - 4:15 PM Presentation: 4:00 PM Session: 723	Angel Earle
Computational Structural Genomics Meets Cryo-EM for the Analyses of Mitochondria-Encoded Enzyme Complexes: A Transformational Approach for Deep Variant Phenotyping in Myelodysplastic Neoplasms	Oral	4:30 PM - 6:00 PM Presentation: 4:45 PM Session: 893	Jing Dong
Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis	Oral	4:30 PM - 6:00 PM Presentation: 5:15 PM Session: 722	Sameem Abedin
Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry	Poster	6:00 PM - 8:00 PM Session: 623	Daniel Landsburg
Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis	Poster	6:00 PM - 8:00 PM Session: 722	Robert Soiffer
To Treat or Not to Treat: Factors Associated with Receipt of Allogeneic Hematopoietic Cell Transplant	Poster	6:00 PM - 8:00 PM Session: 903	Jaime Preussler
Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry	Poster	6:00 PM - 8:00 PM Session: 906	Kitsada Wudhikarn